Claroid Pharmaceuticals Ltd. IPO Details
Claroid Pharmaceuticals was incorporated on August 31, 2018. The company develops and manufactures generic pharmaceutical products, including tablets, ointments and hard gelatin capsules. Its business is primarily export-focused, supplying pharmaceutical products to semi-regulated international markets, particularly in Africa
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 12.6 M | - | - | ₹0 | DRHP DOC |
Claroid Pharmaceuticals issue details
Claroid Pharmaceuticals has 12.6 M shares on offer
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Claroid Pharmaceuticals IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Claroid Pharmaceuticals NUMBER OF SHARES ON OFFER
Claroid Pharmaceuticals FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY26 | 169.7 | 22.7 | 17.0 | 7.4 | 24.1% |
| FY25 | 99.7 | 7.2 | 15.2 | -3.2 | 14.4% |
| FY24 | 63.0 | 4.1 | -2.5 | -4.4 | 18.7% |
Claroid Pharmaceuticals INFORMATION ON IPO ISSUE
About Claroid Pharmaceuticals
Claroid Pharmaceuticals was incorporated on August 31, 2018. The company develops and manufactures generic pharmaceutical products, including tablets, ointments and hard gelatin capsules. Its business is primarily export-focused, supplying pharmaceutical products to semi-regulated international markets, particularly in Africa
Object of the Issue
- Funding of capital expenditure requirement for setting up of the proposed plant
- General corporate purposes
Claroid Pharmaceuticals - PROMOTERS
| Name |
|---|
| Baiju Bhupendrabhai Desai |
| Soni Snehalkumar Hasmukhlal |
| Rushin Baijubhai Desai |
| Patel Shaileshbhai Arjanbhai |
| Patel Ghanshyam Arjanbhai |
Claroid Pharmaceuticals - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Baiju Bhupendrabhai Desai | Managing Director |
| Patel Ghanshyam Arjanbhai | Chairman & Non-Executive Director |
| Soni Snehalkumar Hasmukhlal | Whole Time Director |
| Patel Shaileshbhai Arjanbhai | Whole Time Director |
| Rushin Baijubhai Desai | Whole Time Director |
| Harsh Hemantkumar Shah | Non-Executive and Independent Director |
| Bhalodia Krushnakant | Non-Executive and Independent Director |
| Amin Paragi Kamlesh | Non-Executive and Independent Director |
| Patel Devansh Maheshbhai | Non-Executive and Independent Director |
| Sagar Nishith Soni | Non-Executive and Independent Director |
Claroid Pharmaceuticals Book Running Lead Manager
Oneview Corporate Advisors Private Limited
ipo@oneviewadvisors.com
Valmiki Leela Capital Private Limited
claroid.ipo@valmikileela.com
Claroid Pharmaceuticals Registrar to the Offer
MUFG Intime India Private Limited
claroid.ipo@in.mpms.mufg.com
Claroid Pharmaceuticals Strengths
Diversified product portfolio
Claroid manufactures multiple pharmaceutical dosage forms, including tablets, hard gelatin capsules and ointments, supported by a diversified product portfolio. Its offerings include pain management, anti-inflammatory, antibiotic, anti-malarial, dermatological and approved narcotic products
Export-oriented business model
The company has established a growing export presence across international markets, with Nigeria as its largest export destination. Export revenue increased from Rs 25.84 crore in FY22 to Rs 64.72 crore in FY25, while its presence expanded to Tanzania, Kenya, Myanmar, Zanzibar and Botswana, strengthening its reach across African pharmaceutical markets
Integrated manufacturing infrastructure
The company operates a modern pharmaceutical manufacturing facility spanning approximately 12,332 square metres, with dedicated production lines for tablets, capsules and ointments. The facility is supported by advanced HVAC systems and 51 Air Handling Units (AHUs) designed to meet international pharmaceutical standards
Claroid Pharmaceuticals Risks
Compliance risks
The company has previously experienced delays in obtaining certain environmental approvals and has operated its manufacturing facility above the capacity permitted under the CTE, with the requisite application filed subsequently. Non-compliance with environmental laws or approval conditions, or delays in obtaining or renewing approvals, may result in penalties, regulatory action, operational restrictions or suspension and adversely affect its business and financial performance
Product quality risk
The company’s pharmaceutical products and manufacturing processes are subject to stringent quality standards, and any manufacturing defects, contamination or deviations may result in product rejection, recalls, order cancellations, regulatory action or product liability claims. Such quality issues could lead to additional costs, customer loss, litigation and reputational damage, adversely affecting the company’s business and financial performance
Customer pricing pressure
The company may face pricing pressure from customers and competition, which could lead to price erosion, lower revenue growth and reduced margins. If it cannot reduce production costs or improve efficiency in line with declining market prices, it may have to supply products at lower margins or losses, adversely affecting its business and financial performance
IPO FAQs
The promoters of the company are Baiju Bhupendrabhai Desai, Soni Snehalkumar Hasmukhlal, Rushin Baijubhai Desai, Patel Shaileshbhai Arjanbhai and Patel Ghanshyam Arjanbhai.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.